The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

Duvelisib is an orally active dual inhibitor of PI3K-δ and PI3K-γ in clinical development in hematologic malignancies (HM). To identify novel pairings for duvelisib in HM, it was evaluated alone and in combination with 35 compounds comprising a diverse panel of standard-of-care agents and emerging d...

Descripción completa

Detalles Bibliográficos
Autores principales: Faia, Kerrie, White, Kerry, Murphy, Erin, Proctor, Jennifer, Pink, Melissa, Kosmider, Nicole, McGovern, Karen, Kutok, Jeffery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070190/
https://www.ncbi.nlm.nih.gov/pubmed/30067771
http://dx.doi.org/10.1371/journal.pone.0200725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070190/
https://www.ncbi.nlm.nih.gov/pubmed/30067771
http://dx.doi.org/10.1371/journal.pone.0200725

Ejemplares similares